PEXEVA Drug Patent Profile

Which patents cover Pexeva, and when can generic versions of Pexeva launch?

Pexeva is a drug marketed by Sebela Ireland Ltd and is included in one NDA.

The generic ingredient in PEXEVA is paroxetine mesylate. There are thirty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pexeva

A generic version of PEXEVA was approved as paroxetine mesylate by ACTAVIS LABS FL INC on June 20^th, 2017.

Summary for PEXEVA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PEXEVA

US Patents and Regulatory Information for PEXEVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sebela Ireland Ltd	PEXEVA	paroxetine mesylate	TABLET;ORAL	021299-001	Jul 3, 2003		DISCN	Yes	No
Sebela Ireland Ltd	PEXEVA	paroxetine mesylate	TABLET;ORAL	021299-004	Jul 3, 2003		DISCN	Yes	No
Sebela Ireland Ltd	PEXEVA	paroxetine mesylate	TABLET;ORAL	021299-002	Jul 3, 2003		DISCN	Yes	No
Sebela Ireland Ltd	PEXEVA	paroxetine mesylate	TABLET;ORAL	021299-003	Jul 3, 2003		DISCN	Yes	No

International Patents for PEXEVA

See the table below for patents covering PEXEVA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0994872	COMPOSES 4-PHENYLPIPERIDINE (4-PHENYLPIPERIDINE COMPOUNDS)
Germany	20220955
Greece	3035784
Germany	69704679
South Korea	20010013615
Denmark	0994872

Summary

Last updated: February 3, 2026

PEXEVA (tucatinib) is a targeted therapy developed by Seattle Genetics for HER2-positive breast cancer. It has gained approval based on clinical trial data demonstrating improved progression-free survival (PFS) in specific patient populations. Its market potential hinges on competitive positioning, patent life, regulatory developments, and ongoing clinical trials. Investment in PEXEVA requires assessing its commercial prospects, patent protections, R&D pipeline, and competitive landscape.

---

What Is the Clinical and Regulatory Profile of PEXEVA?

PEXEVA is an oral tyrosine kinase inhibitor targeting HER2 (human epidermal growth factor receptor 2). It received FDA approval in April 2021 as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer, in combination with trastuzumab and capecitabine.

Key clinical data:

• The phase III HER2CLIMB trial showed a median PFS of 7.8 months versus 5.6 months with trastuzumab and capecitabine alone.
• The overall response rate (ORR) was approximately 47% in the tucatinib arm.
• The drug demonstrated a manageable safety profile, with diarrhea and palmar-plantar erythrodysesthesia as common adverse events.

Regulatory status:

• Approved by the FDA under accelerated approval pathways.
• Pending or under review in EMEA, Japan, and other markets.
• Orphan drug designation for various indications enhances exclusivity prospects.

---

What Are the Market Fundamentals and Commercial Potential?

Market size:

Patient Population	Estimated Annual Patients (Global)	Growth Dynamics
HER2-positive breast cancer	200,000	Stable, with rising detection rates
Recurrent/metastatic cases	150,000	Slight annual growth

Market penetration:

• PEXEVA competes primarily with trastuzumab, pertuzumab, T-DM1, and poziotinib.
• Assuming initial market share of 15-20% in eligible patients within 3 years of launch.
• Pricing: Estimated at $12,000–$15,000 per month based on pricing trends for targeted therapies.

Revenue potential:

Assumptions	Estimates (USD billions)
Year 1 sales	0.2–0.4
Year 3 sales	0.6–1.2
Peak sales (Year 5)	1.0–2.0

Price erosion: Patent expiration, biosimilar competition, or price regulation could limit revenue growth over time.

---

What Is the Patent and Competitive Landscape?

Patents:

• Primary patent protection lasts until 2030–2035.
• Patent families cover the composition of matter, method of use, and manufacturing process.
• Patent stability is critical; patent litigation or challenges can extend or shorten exclusivity.

Competitive drugs:

• Tucatinib vs. competitors: Its specificity for HER2 makes it potentially more effective and less toxic.
• Emerging therapies: ADCs, bispecific antibodies, and novel TKIs could challenge tucatinib’s market share.
• Biosimilars: Not yet available for tucatinib, providing a window of market exclusivity.

---

What Are R&D and Pipeline Developments?

Ongoing trials:

• Evaluating tucatinib in earlier-line settings and in combination with other agents.
• Studies in gastric and colorectal cancers expressing HER2.

Pipeline prospects:

• Combination strategies may expand indications.
• Molecular biomarkers could refine patient selection and improve outcomes.

Potential risks:

• Failure in ongoing trials.
• Regulatory delays or adverse safety findings.

---

What Are the Investment Risks?

• Patent challenges or late-stage safety issues could impair profitability.
• Competitive advances or new therapeutic classes may hinder market share.
• Market access restrictions or pricing pressures could limit revenue growth.
• Patent expiration approaching in the next decade necessitates pipeline diversification.

---

Key Takeaways

• PEXEVA is a targeted HER2 inhibitor approved for metastatic breast cancer with solid clinical backing.
• Market potential is significant but constrained by competition and patent timing.
• Commercial success depends on market penetration, pricing strategies, and future pipeline developments.
• Risks include patent challenges, pipeline attrition, and competitive innovations.

---

FAQs

1. When does patent protection for PEXEVA expire?

Patent protection extends roughly until 2030–2035, depending on jurisdictions and legal challenges.

2. What is the main competitive advantage of PEXEVA?

Its specificity for HER2 and manageable toxicity profile differentiate it from broader TKIs and chemotherapies.

3. Are there major competitors expected to impact PEXEVA’s market share?

Yes; ADCs like trastuzumab deruxtecan and HER2 bispecific antibodies are potential competitors.

4. What pipeline therapies could threaten PEXEVA’s future?

Emerging HER2-targeting agents with better efficacy or safety profiles, and combination regimens expanding the use of HER2 inhibitors.

5. How does the cost of PEXEVA compare to alternatives?

Estimated at $12,000–$15,000 per month, aligning with similar targeted therapies but subject to pricing reforms in different markets.

---

Sources

1. FDA approval announcement for tucatinib (2021).
2. HER2CLIMB clinical trial data [2].
3. Analysis of breast cancer market size and growth [3].
4. Patent landscape reports [4].
5. Competitive landscape reports on HER2-targeted therapies [5].

[1] FDA. "FDA Grants Accelerated Approval to Tucatinib," 2021.
[2] Murthy RK et al. NEJM, 2020.
[3] Global Market Insights. "Breast Cancer Market Analysis," 2022.
[4] Patent databases, 2023.
[5] EvaluatePharma, 2022.